Tumor suppressor genes in myeloid differentiation and leukemogenesis. (March 2009)

• Record Type: Journal Article
• Authors: Britschgi, Christian; Fey, Martin F
• Is Part Of: Future oncology. Volume 5:Number 2(2009)
• Page Start: 245
• Page End: 257
• Publication Date: 2009-03
• Subjects: acute myeloid leukemia -- ARF -- chronic myeloid leukemia -- INK4a -- p53 -- PML -- tumor suppressor gene; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/14796694.5.2.245
• Languages: English
• ISSNs: 1479-6694

Abstract

Tumor suppressor genes, such as p53, RB, the INK4-ARF family and PML, suppress malignant transformation by regulating cell cycle progression, ensuring the fidelity of DNA replication and chromosomal segregation, or by inducing apoptosis in response to potentially deleterious events. In myeloid leukemia, hematopoietic differentiation resulting from highly coordinated, stage-wise expression of myeloid transcription and soluble signaling factors is disrupted leading to a block in terminal differentiation and uncontrolled proliferation. This virtually always involves functional inactivation or genetic disruption of one or several tumor suppressor genes in order to circumvent their checkpoint control and apoptosis-inducing functions. Hence, reactivation of tumor suppressor gene function has therapeutic potential and can possibly enhance conventional cytotoxic chemotherapy. In this review, we focus on the role of different tumor suppressor genes in myeloid differentiation and leukemogenesis, and discuss implications for therapy.